Ibrucent Ibrutinib is an anti-cancer medicine. It works by blocking an abnormal protein that signals cancer cells to multiply. Ibrucent Ibrutinib helps stop the spread of cancer cells.
FAQ about Ibrucent Ibrutinib
Q: What are ibrutinib side effects?
Ibrucent has some side effects
- Difficulty having a bowel movement.
- heartburn or indigestion
- muscle stiffness or spasms
- small red or purple spots on the skin
- stomach discomfort, upset, or pain
- swelling or inflammation of the mouth
Q: What is the cost of ibrucent ibrutinib?
In the US ibrutinib costs $484 per capsule/tablet regardless of the strength 140mg. source here
In the UK the cost of a year’s course of ibrutinib treatment is £55,954.50 (excluding VAT) source here
But you can get this medicine at an affordable price from us. for order contact us
Q: What is the drug ibrutinib used for?
Ibrutinib is a type of targeted cancer drug. It is a treatment for mantle cell lymphoma. Chronic lymphocytic leukemia
Q: What cancers does ibrutinib treat?
A drug used alone or with other drugs to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia (a type of non-Hodgkin lymphoma), mantle cell lymphoma, or marginal zone lymphoma.
Q: How quickly does ibrutinib work?
Ibrutinib is a very effective CLL drug and provides evidence of rapid patient benefit concerning symptoms improving, lymph nodes decreasing, and blood counts improving. For some, a very good partial or clinical complete response can emerge clinically within 3-6 months
Dosage & Administration
MCL: 560 mg taken orally once daily (four 140 mg capsules once daily)
CLL and WM: 420 mg taken orally once daily (three 140 mg capsules once daily)
Take capsules orally with a glass of water. Do not open, break, or chew them.
Use in Pregnancy & Lactation
Pregnancy Category D
Based on animal data, Ibrutinib can cause fetal harm when administered to a pregnant woman. The patient should be informed of the potential hazard to the fetus if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug.
It is unknown whether Ibrutinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for severe adverse reactions in nursing infants from Ibrutinib, a decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.
There is no evidence that Ibrutinib is safe or effective in pediatric patients.
There were no overall differences in safety or effectiveness between elderly and younger subjects. There were also no overall differences in effectiveness between these patients and younger patients. Cardiac adverse events (atrial fibrillation and hypertension), infections (pneumonia, urinary tract infection, and cellulitis), and gastrointestinal events (diarrhea and dehydration) occurred more frequently among elderly patients.